Cullinan Therapeutics Reports Anti-Leukemic Activity in Phase 1 CLN-049 Study

Bitget2026/11/04 14:17

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Cullinan Therapeutics will present CLN-049 and velinotamig research at the ASH annual meeting in New Orleans, December 12-15, 2026.
A Phase 1 abstract reports CLN-049 anti-leukemic activity with a favorable safety profile in relapsed or refractory leukemia or myelodysplastic syndrome.
Updated results for CLN-049 regimens selected for Phase 2 will be presented December 13.
Trial-in-progress posters cover CLN-049 combination treatment for newly diagnosed acute myeloid leukemia and velinotamig for autoimmune cytopenias.
Preclinical findings to be presented show velinotamig selectively targets BCMA-expressing B-lineage cells driving autoimmune cytopenias.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cullinan Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-446348), on November 04, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Cullinan Therapeutics Reports Anti-Leukemic Activity in Phase 1 CLN-049 Study

You may also like

Crypto prices